BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Motion DNA Corp. CEO Issues Open Letter To Shareholders


10/19/2005 5:12:51 PM

SCOTTSDALE, Ariz., Sept. 14 /PRNewswire/ -- The following is an Open Letter to Shareholders and other interested parties issued by Zig Ziegler, Founder and Chairman of Motion DNA Corp. .

Mr. Ziegler:

"In response to the many calls and Emails we have received, requesting an update regarding the progress of our ongoing discussions with Jamir Miller, General Partner of Formula 51-2 LLC, we felt it would be prudent and appropriate to issue a statement at this time."

"Along with Bryan Greenwood, Chief Financial Officer, we are currently writing an addendum to our Business Plan, specifically outlining the Use of Proceeds, if and when there may be an infusion of capital by Formula 51-2. We expect to finish this document and present it to 51-2 in a week or so."

"Over the past several weeks, Mr. Miller and I have been exploring many possibilities, any of which could result in an investment or acquisition by Formula 51-2 of Motion DNA. We have discussed a plethora of avenues, including their purchasing Motion DNA common stock in the open market, investing in short-term convertible debentures and warrants, and buying some of the founder's stock."

"At this point the structure of the deal has not been formalized. I need to stress that although Mr. Miller's intention is to make a significant investment to ensure the longevity of our Company and its mission, nothing should be implied that there is any guarantee that a deal will be sealed."

"I am committed, along with our Board of Directors, that we will do everything to enhance the shareholder value of our common stock, and ultimately we intend to make the right financial and strategic decisions for all of our stockholders with regard to Formula 51-2."

"We intend to investigate every possible avenue for an agreement with Formula 51-2. If an agreement cannot be reached with Formula 51-2 by the close of business on October 14, 2005, we will begin to explore opportunities with other interested parties. We would like to take this opportunity to thank each and every shareholder who has taken the time to contact us. We read every Email and field as many calls as humanly possible. We sincerely appreciate your continued interest in, and loyalty to, your Company-Motion DNA."

About Motion DNA

Motion DNA, a Scottsdale, Arizona-based company, has developed several products utilizing advanced motion-capture technology that provides a significant service to the sports community.

The Company has developed advanced systems designed for coaches, trainers and other professionals that are valuable tools for analyzing the specific athletic movements found in baseball, softball, golf, running, and more. Motion DNA blends sports and science to maximize athletic performance and reduce injuries.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward- looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors. The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

For more information on Motion DNA Contact: Motion DNA Corporation 15023 N. 73rd Street Scottsdale, Arizona 85260 1.877.425.7734 toll free 480.425.7734 phone 480.991.7736 fax Investor Relations AGORA Investor Relations http://www.agoracom.com/IR/MotionDNAMTDX@Agoracom.com Our new investor website: www.agora.com

Motion DNA Corp.

CONTACT: Zig Ziegler, CEO of Motion DNA Corporation, toll free,+1-877-425-7734, or +1-480-425-7734, or fax, +1-480-991-7736; or InvestorRelations, AGORA Investor Relations, MTDX@Agoracom.com, for Motion DNACorp.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES